Covid-19: Scientists find antibodies effective against all variants

Covid-19: Scientists find antibodies effective against all variants


The research also revealed that hybrid immunity provides superior antibody-based protection against future exposure to the virus.




Scientists have identified an antibody capable of neutralizing all known variants of Sars-CoV-2, the virus responsible for Covid-19. Called SC27, the antibody was discovered and isolated from a single patient by a group of researchers led by the University of Texas at Austin. The details of the discovery were published in the journal Medicine of cellular relationships.

As part of a study on hybrid immunity – which results from the combination of infection and vaccination – the team managed to isolate the SC27 antibody using advanced technologies developed over years of research. Obtaining the precise molecular sequence of the antibody opens the possibility of its large-scale production for future treatments.

“The future discovery of SC27 and similar antibodies will help protect the population from current and future variants of Covid.”

Symptoms of Covid, Flu and Sinusitis: What's the Difference?
Symptoms of Covid, Flu and Sinusitis: What’s the Difference?

Since its identification, Sars-CoV-2 has evolved rapidly, becoming resistant to vaccines and treatments developed to date. The goal of current research is to create a universal vaccine capable of generating antibodies and a broad immune response, offering protection against the virus and its mutations.

The SC27 antibody works by binding to the virus’s spike protein, a structure essential for infecting human cells. By blocking this protein, the antibody prevents infection.

In addition to identifying the antibody, the research found that hybrid immunity provides superior antibody-based protection against future exposure to the virus, compared to protection obtained from infection or vaccination alone.

To isolate SC27, the researchers used Ig-Seq technology, which combines single-cell DNA sequencing with proteomic analysis. This technology provides detailed insight into the antibody response to both infection and vaccination.

Source: Terra

You may also like